CryoPort Inc (CYRX) Given $11.20 Consensus Target Price by Analysts

Shares of CryoPort Inc (NASDAQ:CYRX) have been given an average broker rating score of 1.25 (Strong Buy) from the four brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating and three have given a strong buy rating to the company.

Brokers have set a one year consensus target price of $11.20 for the company and are expecting that the company will post ($0.09) EPS for the current quarter, according to Zacks. Zacks has also assigned CryoPort an industry rank of 59 out of 265 based on the ratings given to related companies.

A number of research analysts have recently weighed in on CYRX shares. Needham & Company LLC restated a “buy” rating and issued a $11.00 target price (up previously from $10.00) on shares of CryoPort in a report on Thursday. Roth Capital started coverage on CryoPort in a report on Thursday, November 30th. They issued a “buy” rating and a $12.50 target price on the stock.

Shares of CryoPort (NASDAQ CYRX) traded down $0.14 during trading hours on Wednesday, reaching $9.83. The company’s stock had a trading volume of 349,955 shares, compared to its average volume of 121,809. CryoPort has a 1-year low of $1.96 and a 1-year high of $10.40. The company has a market capitalization of $272.58, a price-to-earnings ratio of -29.11 and a beta of 0.71.

CryoPort (NASDAQ:CYRX) last posted its earnings results on Tuesday, March 6th. The consumer goods maker reported ($0.09) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.02). CryoPort had a negative net margin of 66.09% and a negative return on equity of 47.36%. The company had revenue of $3.33 million during the quarter, compared to the consensus estimate of $3.37 million. The business’s revenue was up 49.5% compared to the same quarter last year. equities analysts predict that CryoPort will post -0.25 earnings per share for the current year.

Several hedge funds have recently bought and sold shares of the company. Northern Trust Corp lifted its holdings in shares of CryoPort by 105.0% in the second quarter. Northern Trust Corp now owns 22,179 shares of the consumer goods maker’s stock valued at $109,000 after purchasing an additional 11,358 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in CryoPort during the third quarter worth $118,000. US Bancorp DE lifted its holdings in CryoPort by 100.9% during the fourth quarter. US Bancorp DE now owns 25,487 shares of the consumer goods maker’s stock worth $219,000 after acquiring an additional 12,803 shares during the period. Thompson Davis & CO. Inc. lifted its holdings in CryoPort by 74.5% during the fourth quarter. Thompson Davis & CO. Inc. now owns 30,100 shares of the consumer goods maker’s stock worth $259,000 after acquiring an additional 12,850 shares during the period. Finally, Bank of Montreal Can bought a new stake in CryoPort during the fourth quarter worth $142,000. Institutional investors own 22.83% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “CryoPort Inc (CYRX) Given $11.20 Consensus Target Price by Analysts” was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this piece can be read at

CryoPort Company Profile

Cryoport, Inc (Cryoport) is a provider of cryogenic logistics solutions to the life sciences industry through its purpose-built packaging, information technology and specialized cold chain logistics expertise. The Company provides logistics solutions for biologic materials, such as immunotherapies, stem cells, chimeric antigen receptors (CAR)-T cells, and reproductive cells for clients.

Get a free copy of the Zacks research report on CryoPort (CYRX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with's FREE daily email newsletter.

Leave a Reply